evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

21 questions · 21 findings · 2 reviews · Neuromuscular

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 7 · 33.3%GRADE not reported 0 · 0%Very low 3 · 14.3%Low 5 · 23.8%Moderate 5 · 23.8%High 1 · 4.8%

IVIg vs SCIg

Induction of labour · people with multifocal motor neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

IVIg vs SCIg

Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal · people with multifocal motor neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

IVIg vs SCIg

Adverse events · people with multifocal motor neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

IVIg vs SCIg

Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy

It is very uncertain whether IVIg changes proportion of participants with side effects attributable to treatment compared with SCIg (very low certainty).

1 finding from 1 review

IVIg vs placebo

Proportion of participants with an improvement in disability scale used in the original study · people with multifocal motor neuropathy

IVIg showed no clear difference in proportion of participants with an improvement in disability scale… compared with placebo (low certainty).

1 finding from 1 review

IVIg vs placebo

Proportion of participants with an improvement of muscle strength · people with multifocal motor neuropathy

IVIg may leads to higher proportion of participants with an improvement of muscle strength compared with placebo (low certainty).

1 finding from 1 review

IVIg vs placebo

Proportion of participants with an improvement in disability at 12 months or later · people with multifocal motor neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

IVIg vs placebo

Proportion of participants in which at least 1 conduction block resolved after therapy · people with multifocal motor neuropathy

IVIg showed no clear difference in proportion of participants in which at least 1 conduction block… compared with placebo (low certainty).

1 finding from 1 review

IVIg vs placebo

Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal · people with multifocal motor neuropathy

IVIg probably leads to higher proportion of IVIg‐treated participants with an increase in… compared with placebo (moderate certainty).

1 finding from 1 review

IVIg vs placebo

Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal · people with multifocal motor neuropathy

IVIg probably leads to lower proportion of IVIg‐treated participants with a decrease in muscle… compared with placebo (moderate certainty).

1 finding from 1 review

IVIg vs placebo

Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy

It is very uncertain whether IVIg changes proportion of participants with side effects attributable to treatment compared with placebo (very low certainty).

1 finding from 1 review

IVIg vs PE

Number improved by 1 or more disability grades after 4 weeks · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in number improved by 1 or more disability grades after 4 weeks compared with PE (moderate certainty).

1 finding from 1 review

IVIg vs PE

Dead or disabled after 12 months (48 weeks) · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in dead or disabled after 12 months (48 weeks) compared with PE (low certainty).

1 finding from 1 review

IVIg vs PE

Relapse or treatment‐related fluctuation · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in relapse or treatment‐related fluctuation compared with PE (low certainty).

1 finding from 1 review

IVIg vs PE

Patients in whom treatment was discontinued · patients with Guillain‐Barré syndrome

IVIg leads to lower participants in whom treatment was discontinued compared with PE (high certainty).

1 finding from 1 review